Covance CVD

  1. All
  2. Commentary
  3. Headlines
    1. LabCorp Sees Early Benefits From Covance Deal


      Fri, 20 Feb 2015

      LabCorp finished off 2014 with strong performance in the fourth quarter, and our minor adjustments did not materially move the needle on our $127 fair value estimate. With year-over-year revenue growth hitting our estimates on the nose, LabCorp also managed to largely match our projections on the

    2. From Barron’s, January 26, 2015 (Part 1)


      Sat, 24 Jan 2015

      attention to Q4 earnings. There are significant execution risks in Lab Corp Am [ LH ] pending expensive acquisition of Covance [ CVD ]; S&P has downgraded the debt from BBB to BBB-. A turnaround of Urban Outfitters [ URBN ] is possible; Barron

    3. Strong Revenue Growth Continues at WuXi, but Margin Contraction Weighs on Earnings Growth


      Thu, 13 Nov 2014

      posted strong growth of 11%. This was well in excess of the 3%-7% growth posted by early-stage U.S. peers Covance and Charles River, although WuXi is growing off a much smaller base. Longer term, we expect the U.S. business to

    4. LabCorp Takeover Offers Attractive Price for Covance Shareholders


      Mon, 3 Nov 2014

      Covance announced that it has agreed to be acquired by LabCorp for a mixture of cash and stock equal to approximately $105 per Covance share. For Covance shareholders, we think LabCorp’s offer represents an attractive

    5. LabCorp Plans for Covance Acquisition; Our Fair Value Estimate Stands


      Mon, 3 Nov 2014

      announcement of its impending acquisition of Covance , we think investors may not fully ..... incorporating our assumptions about the Covance business and LabCorp's financing ..... raising our fair value estimate on Covance to the $105 offer price. We think

    6. Charles Rivers Posts Strong 2Q Results as Early Stage Demand Finally Returns


      Thu, 7 Aug 2014

      year. We believe this segment is the best comparison to Covance 's early-stage business, and Charles River’s performance compares favorably to Covance 's early-stage reported revenue of 7.7%. While Charles

    7. Quintiles Posts Solid 2Q, Weak Bookings Unlikely to Be a Cause for Concern


      Thu, 31 Jul 2014

      rather than a more concerning slowdown in demand. Based on the strong book/bill ratios we have seen out of its peers Covance and ICON, which have already reported this quarter, we are inclined to agree with management. The firm's less attractive

    8. Covance Posts Light Results Relative to Peers, but Still on Track to Meet Full-Year Estimates


      Fri, 2 May 2014

      Covance reported first-quarter results that slightly ..... industrywide overcapacity and weak demand, but Covance has shown signs of improvement. The segment has ..... however, it was boosted by 10.9% growth in Covance ’s large central lab business. The clinical

    9. Charles River Posts Solid 4Q as Preclinical Services Finally Rebound


      Thu, 13 Feb 2014

      growth since 2008. Management stated it is stealing market share from competitors, which we believe is accurate given that Covance reported just 5% revenue growth for its early-stage business in the fourth quarter.

    10. Covance 4Q Results Meet Expectations, Early-Stage Business Shows Signs of Improvement


      Wed, 5 Feb 2014

      Covance reported solid fourth-quarter results that ..... growth in the clinical development business. Covance ’s book-to-bill ratio held steady at ..... growth is sustainable over the near term. Covance was able to leverage the strong growth into

    « Prev12345Next »
    Content Partners